Trials / Unknown
UnknownNCT00217763
European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients
A Phase III Study of the Efficacy and Safety of 3APS as Add-on Therapy in Mild to Moderate Alzheimer's Disease
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 930 (estimated)
- Sponsor
- Bellus Health Inc. - a GSK company · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 3 study is to evaluate the efficacy and safety of 3APS as an add-on therapy to most standard medication for Alzheimer's disease compared to placebo (inactive substance pill) in patients with mild to moderate Alzheimer's disease.
Detailed description
* Duration of treatment: 18 months * 3 treatment arms: Placebo and 2 different doses of active drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 3APS |
Timeline
- Start date
- 2005-09-01
- Completion
- 2007-12-01
- First posted
- 2005-09-22
- Last updated
- 2007-12-10
Locations
69 sites across 10 countries: Belgium, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00217763. Inclusion in this directory is not an endorsement.